Haleon (HLN.L)
A leading global consumer healthcare business managing a portfolio of world-class brands in pain relief, oral health, and wellness.
What Haleon does
Haleon is a global consumer healthcare company focused on the development, manufacture, and distribution of over-the-counter (OTC) medicines, oral health products, and nutritional supplements. The company's portfolio includes well-known brands across categories such as pain relief, respiratory health, digestive health, and vitamins/minerals.
Themes: consumer staples, OTC medicines, oral health, wellness and supplements
Fundamentals
- Price£3.62 as of 2026-08-03 close
- Market capn/a company fundamentals are not available for UK-listed companies in our data
- 1-year return-0.8% 2025-08-01 close £3.65 → 2026-08-03 close £3.62
- P/En/a company fundamentals are not available for UK-listed companies in our data
- Net marginn/a company fundamentals are not available for UK-listed companies in our data
- Gross marginn/a company fundamentals are not available for UK-listed companies in our data
- ROEn/a company fundamentals are not available for UK-listed companies in our data
- Debt / equityn/a company fundamentals are not available for UK-listed companies in our data
- Revenue growth (YoY)n/a company fundamentals are not available for UK-listed companies in our data
- Revenue CAGR (3y)n/a company fundamentals are not available for UK-listed companies in our data
- Betan/a we do not track a market benchmark for UK-listed companies
Dividend: company fundamentals are not available for UK-listed companies in our data.
How Haleon looks technically
Haleon (HLN.L) is trading 0.2% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 60 trading days ago — a "death cross", a bearish long-term signal. A strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 26, with buyers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 50, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bearish about 2 trading days ago (its momentum flipped negative). It made a new 20-day high about 5 trading days ago. Day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 1% of the past ~6 months), which often precedes a bigger move. Trading volume is unusually light — only about 0% of its 30-day average.
Trend
| Distance from the 200-day | -0.2% | it is trading 0.2% below its 200-day average, the long-term trend line — a long-term downtrend |
|---|---|---|
| 50-day moving average | £3.50 | its average price over the last 50 trading days — a short-term trend line — is £3.50 |
| 200-day moving average | £3.63 | its average price over the last 200 trading days — the long-term trend line — is £3.63 |
| Since the 50/200 cross | 60 sessions | its 50-day average crossed below its 200-day average about 60 trading days ago — a "death cross", a bearish long-term signal |
| Trend strength (14-day ADX) | 26.3 | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 26, with buyers in control |
Momentum
| 14-day RSI | 50.0 | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 50, neither overbought (above 70) nor oversold (below 30) |
|---|---|---|
| Since the MACD crossed zero | 2 sessions | MACD, a trend-momentum gauge, turned bearish about 2 trading days ago (its momentum flipped negative) |
Range
| 52-week high | £4.16 | its highest closing price over the past year (about 252 trading days) was £4.16 |
|---|---|---|
| From the 52-week high | -12.9% | it is 12.9% below its 52-week high (its highest price of the past year) |
| Above the 52-week low | +32.0% | it is 32.0% above its 52-week low (its lowest price of the past year) |
| Below the 52-week high | 12.9% | it is 12.9% below its highest point of the past year |
| Since a 20-day breakout | 5 sessions | it made a new 20-day high about 5 trading days ago |
| Since a 55-day breakout | 5 sessions | it made a new 55-day high about 5 trading days ago |
| All-time high | £4.20 | its highest closing price on record is £4.20 (set on 2025-05-30) |
| From the all-time high | -13.6% | it is 13.6% below its all-time high |
| All-time low | £0.03142 | its lowest closing price on record is £0.03142 (set on 2023-09-04) |
| Above the all-time low | +11,433% | it is 11432.7% above its all-time low |
Volatility
| Band width vs its own 6 months | 0th percentile | day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 1% of the past ~6 months), which often precedes a bigger move |
|---|---|---|
| Bollinger bands (20-day, ±2σ) | £3.55 – £3.67 – £3.79 | most of its recent trading has stayed between about £3.55 and £3.79 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles |
Volume
| Volume vs its 30-day average | 0.00× | trading volume is unusually light — only about 0% of its 30-day average |
|---|
Screens: Trading below the 200-day moving average · MACD just crossed bearish (12/26/9) · in a Bollinger Band volatility squeeze · in a strong, established uptrend (ADX) | Learn: moving average · golden cross · adx · rsi · macd · breakout · bollinger bands · volume and relative volume
Based on daily closing prices as of 2026-08-03. Describes past price behavior only — informational, not financial advice.
Key risks (from latest filing)
["intense competition in consumer healthcare markets","dependence on consumer spending and brand perception","regulatory risks regarding product safety and labeling"]
Competitors & peers
- Johnson & Johnson (JNJ)
- GSK (GSK)
- Procter & Gamble (PG)
- Sanofi (SNY)
- Reckitt Benckiser (RKT.L)
- Bayer (BAYN.DE)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare HLN.L vs…
Frequently asked questions
What does Haleon (HLN.L) do?
Haleon is a global consumer healthcare company focused on the development, manufacture, and distribution of over-the-counter (OTC) medicines, oral health products, and nutritional supplements. The company's portfolio includes well-known brands across categories such as pain relief, respiratory health, digestive health, and vitamins/minerals.
Who are Haleon's (HLN.L) competitors?
Notable peers of Haleon (HLN.L) include Johnson & Johnson, GSK, Procter & Gamble, Sanofi and Reckitt Benckiser. This peer set is informational only — not financial advice.
Is Haleon (HLN.L) overbought or oversold right now?
Haleon (HLN.L) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 50, in the neutral middle (as of 2026-08-03). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on HLN.L come from?
Fundamentals and prices come from market data. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data. Prices are delayed daily-close data.
Last updated 2026-08-03.
Informational only — NOT financial advice. All figures are delayed daily-close data from market data, shown with their as-of date.